𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study

✍ Scribed by Malcolm Lader; Karina Stender; Vera Bürger; Rico Nil

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
125 KB
Volume
19
Category
Article
ISSN
1091-4269

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Escitalopram in the treatment of general
Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study
✍ Jonathan R.T. Davidson; Anjana Bose; Andrew Korotzer; Hongjie Zheng 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (1

Efficacy and tolerability of duloxetine
Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies
✍ Jonathan Davidson; Christer Allgulander; Mark H. Pollack; James Hartford; Janell 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

## Abstract ## Objective To assess the efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder (GAD). ## Methods Acute‐phase data from a subset of patients (≥65 years) with GAD were pooled from four randomized, double‐blind, placebo‐controlled trials of dulo

Efficacy of Venlafaxine ER in patients w
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine
✍ Christer Allgulander; Richard Mangano; Jun Zhang; Alv A. Dahl; Ulla Lepola; Inge 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

## Abstract This study evaluated the anxiolytic efficacy, safety and tolerability of a flexible dose of venlafaxine extended release (ER) compared with placebo and paroxetine in the short‐term treatment of generalized social anxiety disorder (SAD). Adult outpatients with generalized SAD (__n__ = 43

Efficacy and tolerability of extended re
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies
✍ Dan J. Stein; Borwin Bandelow; Charles Merideth; Bengt Olausson; Johan Szamosi; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB 👁 2 views

## Objective Prospectively planned pooled analysis evaluating efficacy and tolerability of acute quetiapine XR monotherapy in generalised anxiety disorder. ## Methods Data from three 10‐week, randomised, double‐blind, placebo‐controlled studies of similar design were analysed. ## Results At Wee

Ropinirole is effective in the treatment
Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: A 12-week, double-blind, randomized, parallel-group, placebo-controlled study
✍ Arthur S. Walters; William G. Ondo; Tilman Dreykluft; Ron Grunstein; Daniel Lee; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 1 views

## Abstract Restless legs syndrome (RLS) is a neurological condition with significant impact on sleep and quality of life (QoL). This double‐blind, randomized, 12‐week, multinational study compared the efficacy and safety of ropinirole and placebo in RLS. In total, 267 outpatients with moderate‐to‐

A multicentre, randomized, double-blind,
A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study
✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre